Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer

详细信息    查看全文

• 作者：Chang-Min Choi (1)
  Se-Jin Jang (2)
  Seong-Yeol Park (3)
  Yong-Bock Choi (3)
  Jae-Heon Jeong (4)
  Dae-Seok Kim (3)
  Hyun-Kyoung Kim (3)
  Kang-Seo Park (3)
  Byung-Ho Nam (5)
  Hyeong-Ryul Kim (6)
  Soo-Youl Kim (3)
  Kyeong-Man Hong (3)
  
• 刊名：Molecular Cancer
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：10
• 期：1
• 全文大小：2651KB
• 参考文献：1. Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ: Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. / Oncology 2009, 76:239鈥?46. CrossRef
  2. Coate LE, Leighl NB: How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer? / Curr Treat Options Oncol 2011.
  3. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. / Oncologist 2009, 14:253鈥?63. CrossRef
  4. Lorand L, Graham RM: Transglutaminases: crosslinking enzymes with pleiotropic functions. / Nature Reviews Molecular Cell Biology 2003, 4:140鈥?56. CrossRef
  5. Han JA, Park SC: Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. / J Cancer Res Clin Oncol 1999, 125:89鈥?5. CrossRef
  6. Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D: Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. / Carcinogenesis 2008, 29:1893鈥?900. CrossRef
  7. Mehta K: High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. / International journal of cancer 1994, 58:400鈥?06. CrossRef
  8. Mehta K, Fok J, Miller FR, Koul D, Sahin A: Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. / Clinical cancer research 2004, 10:8068鈥?076. CrossRef
  9. Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM: Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. / J Cancer Res Clin Oncol 2010, 136:493鈥?02. CrossRef
  10. Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA: Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. / J Biol Chem 2009, 284:17914鈥?7925. CrossRef
  11. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, / et al.: Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. / Cancer Res 2008, 68:5849鈥?858. CrossRef
  12. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K: Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. / Oncogene 2007, 26:2459鈥?470. CrossRef
  13. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D: Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. / Cancer Res 2007, 67:7194鈥?202. CrossRef
  14. Chen SH, Lin CY, Lee LT, Chang GD, Lee PP, Hung CC, Kao WT, Tsai PH, Schally AV, Hwang JJ, Lee MT: Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells. / Anticancer Res 30:4177鈥?186.
  15. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM: Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. / J Thorac Oncol 2010, 5:442鈥?47. CrossRef
  16. Jeong JM, Murthy SN, Radek JT, Lorand L: The fibronectin-binding domain of transglutaminase. / J Biol Chem 1995, 270:5654鈥?658. CrossRef
  17. Hang J, Zemskov EA, Lorand L, Belkin AM: Identification of a novel recognition sequence for fibronectin within the NH2-terminal beta-sandwich domain of tissue transglutaminase. / J Biol Chem 2005, 280:23675鈥?3683. CrossRef
  18. Janiak A, Zemskov EA, Belkin AM: Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway. / Mol Biol Cell 2006, 17:1606鈥?619. CrossRef
  19. Lipscomb EA, Mercurio AM: Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. / Cancer Metastasis Rev 2005, 24:413鈥?23. CrossRef
  20. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K: Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. / PLoS One 2010, 5:e13390. CrossRef
  21. Kim D, Park S, Nam B, Kim I, Kim S: Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. / Cancer research 2006, 66:10936鈥?0943. CrossRef
  22. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal B, Mehta K: Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. / Cancer research 2006, 66:8788鈥?795. CrossRef
  
• 作者单位：Chang-Min Choi (1)
  Se-Jin Jang (2)
  Seong-Yeol Park (3)
  Yong-Bock Choi (3)
  Jae-Heon Jeong (4)
  Dae-Seok Kim (3)
  Hyun-Kyoung Kim (3)
  Kang-Seo Park (3)
  Byung-Ho Nam (5)
  Hyeong-Ryul Kim (6)
  Soo-Youl Kim (3)
  Kyeong-Man Hong (3)
  
  1. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, 388-1 Pungnap-2 Dong, SongPa-Gu, Seoul, 138-736, Korea
  2. Department of Pathology, Asan Medical Center, College of Medicine, University of Ulsan, 388-1 Pungnap-2 Dong, SongPa-Gu, Seoul, 138-736, Korea
  3. Cancer Cell and Molecular Biology Branch, Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, 410-769, Korea
  4. Department of Medical Oncology & Hematology, Kyung Hee Medical Center, Kyung Hee University, Seoul, 130-702, Korea
  5. Cancer Biostatics Branch, Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, 410-769, Korea
  6. Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, College of Medicine, University of Ulsan, 388-1 Pungnap-2 Dong, SongPa-Gu, Seoul, 138-736, Korea
  
• ISSN：1476-4598

文摘

Background Expression of transglutaminase 2 (TGase 2) is related to invasion and resistance to chemotherapeutic agents in several cancer cells. However, there has been only limited clinical validation of TGase 2 as an independent prognostic marker in cancer. Methods The significance of TGase 2 expression as an invasive/migratory factor was addressed by in vitro assays employing down-regulation of TGase 2. TGase 2 expression as a prognostic indicator was assessed in 429 Korean patients with early-stage non-small cell lung cancer (NSCLC) by immunohistochemical staining. Results TGase 2 expression increased the invasive and migratory properties of NSCLC cells in vitro, which might be related to the induction of MMP-9. In the analysis of the immunohistochemical staining, TGase 2 expression in tumors was significantly correlated with recurrence in NSCLC (p = 0.005) or in the non-adenocarcinoma subtype (p = 0.031). Additionally, a multivariate analysis also showed a significant correlation between strong TGase 2 expression and shorter disease-free survival (DFS) in NSCLC (p = 0.029 and HR = 1.554) and in the non-adenocarcinoma subtype (p = 0.030 and HR = 2.184). However, the correlation in the adenocarcinoma subtype was not significant. Conclusions TGase 2 expression was significantly correlated with recurrence and shorter DFS in NSCLC, especially in the non-adenocarcinoma subtype including squamous cell carcinoma.